Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction by Kim, Chang Seong et al.
ORIGINAL INVESTIGATION Open Access
Concomitant renal insufficiency and diabetes
mellitus as prognostic factors for acute
myocardial infarction
Chang Seong Kim
1, Joon Seok Choi
1, Jeong Woo Park
1, Eun Hui Bae
1, Seong Kwon Ma
1, Myung Ho Jeong
1,2,
Young Jo Kim
3, Myeong Chan Cho
4, Chong Jin Kim
5 and Soo Wan Kim
1*, for
other Korea Acute Myocardial Infarction Registry Investigators
Abstract
Background: Diabetes mellitus and renal dysfunction are prognostic factors after acute myocardial infarction (AMI).
However, few studies have assessed the effects of renal insufficiency in association with diabetes in the context of
AMI. Here, we investigated the clinical outcomes according to the concomitance of renal dysfunction and diabetes
mellitus in patients with AMI.
Methods: From November 2005 to August 2008, 9905 patients (63 ± 13 years; 70% men) with AMI were enrolled
in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) and were categorized into 4
groups: Group I (n = 5700) had neither diabetes nor renal insufficiency (glomerular filtration rate [GFR] ≥ 60 ml/
min/1.73 m
2), Group II (n = 1730) had diabetes but no renal insufficiency, Group III (n = 1431) had no diabetes but
renal insufficiency, and Group IV (n = 1044) had both diabetes and renal insufficiency. The primary endpoints were
major adverse cardiac events (MACE), including a composite of all cause-of-death, myocardial infarction, target
lesion revascularization, and coronary artery bypass graft after 1-year clinical follow-up.
Results: Primary endpoints occurred in 1804 (18.2%) patients. There were significant differences in composite
MACE among the 4 groups (Group I, 12.5%; Group II, 15.7%; Group III, 30.5%; Group IV, 36.5%; p < 0.001). In a Cox
proportional hazards model, after adjusting for multiple covariates, the 1-year mortality increased stepwise from
Group III to IV as compared with Group I (hazard ratio [HR], 1.96; 95% confidence interval [CI], 1.34-2.86; p = 0.001;
and HR, 2.42; 95% CI, 1.62-3.62; p < 0.001, respectively). However, Kaplan-Meier analysis showed no significant
difference in probability of death at 1 year between Group III and IV (p = 0.288).
Conclusions: Renal insufficiency, especially in association with diabetes, is associated with the occurrence of
composite MACE and indicates poor prognosis in patients with AMI. Categorization of patients with diabetes and/
or renal insufficiency provides valuable information for early-risk stratification of AMI patients.
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Background
Renal dysfunction and diabetes mellitus are established
risk factors for long-term adverse prognosis in patients
with cardiovascular disease. Any degree of preexisting
renal dysfunction should be considered a potent, inde-
pendent risk factor for cardiovascular complication after
acute myocardial infarction (AMI) [1,2]. The 1-year
mortality after AMI is approximately 60% in end-stage
renal disease (ESRD) [3], and renal dysfunction has been
reported to be independently predictive of death after
admission for acute coronary syndrome [4,5], clearly
indicating that the risk of subsequent cardiovascular
events in patients with renal dysfunction is higher than
in subjects with normal renal function [6,7]. Notwith-
standing the imminent risks, the mechanisms by which
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unclear.
The prevalence of diabetes mellitus has rapidly
increased worldwide. Strikingly, diabetes mellitus is
(similar to coronary artery disease) a known risk factor
for cardiovascular events such as myocardial infarction
and cardiovascular death [8,9]. A large, prospective mul-
tinational registry, the Global Registry of Acute Coron-
ary Events (GRACE) [10], revealed that in-hospital
mortality of patients with diabetes concomitant with
acute coronary syndrome is almost twice as high as that
of patients without diabetes. Moreover, in a recent study
[11], diabetes has been suggested as a significant inde-
pendent risk factor for acute coronary syndrome.
Therefore, the presence of diabetes mellitus and renal
dysfunction may individually or simultaneously have a
negative prognostic effect on patients with AMI. Yet
several studies have evaluated mortality in the presence
or absence of diabetes and renal insufficiency after AMI
[12,13], limited information exists on the role of renal
insufficiency and its association with diabetes mellitus in
the context of AMI. The aim of the present study was
to investigate the clinical outcomes according to the
concomitance of renal dysfunction and diabetes mellitus
in patients with AMI.
Methods
Study design and patient population
The study population was enrolled in a nationwide pro-
spective Korea Acute Myocardial Infarction Registry
(KAMIR) from November 2005 to August 2008. This
study was a retrospective cohort of 9905 consecutive
patients (mean age ± standard deviation [SD], 63 ± 13
years; 70% men) whose discharge diagnosis was AMI
based on clinical symptoms, cardiac enzyme levels, and
12-lead electrocardiogram [14]. This study included
patients who were available to calculated estimated
GFR. The patients with underlying malignancy were
excluded. All of the patients completed at least 1 year of
follow-up.
The KAMIR, launched in November 2005, is a Korean
prospective multicenter data collection registry reflecting
real-world treatment practices and outcomes in Asian
patients diagnosed with AMI. The registry consists of 52
community and university hospitals with facilities for
primary percutaneous coronary intervention (PCI),
thrombolytic therapy and on-site cardiac surgery. Data
were collected by a well-trained study coordinator based
on a standardized case report form and protocol. The
study protocol was approved by the ethics committee at
each participating institution and all patients were
informed about their participation in this registry.
For simplicity of analysis and presentation, all patients
were categorized into 4 groups according to the
presence of diabetes mellitus and renal insufficiency
(glomerular filtration rate [GFR] < 60 ml/min/1.73 m
2).
Group I (n = 5700) had neither diabetes mellitus nor
renal insufficiency (GFR ≥ 60 ml/min/1.73 m
2); Group
II (n = 1730) had diabetes mellitus but no renal insuffi-
ciency; Group III (n = 1431) had no diabetes mellitus
but renal insufficiency; Group IV (n = 1044) had both
diabetes mellitus and renal insufficiency.
Definition
Diabetes mellitus was defined as fasting plasma glucose
level of 126 mg/dl or greater on at least 2 occasions,
plasma glucose of 200 mg/dl or greater at 2 h after a
75-g oral glucose tolerance test, the need for insulin or
glucose-lowering medication to control glucose levels on
admission, or medical history of diet-controlled diabetes.
Among AMI patients, ST-segment elevation acute myo-
cardial infarction (STEMI) was defined as new ST-seg-
ment elevation of > 2 mm in ≥ 2 pre-cordial leads or >
1m mi n≥ 2 limb leads, or a new onset of left bundle
branch block on the 12-lead electrocardiogram with a
concomitant increase of at least one cardiac biomarker
of necrosis (e.g., creatine kinase-MB, troponin I, or tro-
ponin T). Non-ST-segment elevation acute myocardial
infarction (NSTEMI) was defined as the exception of
STEMI. Left ventricular ejection fraction (LVEF) was
checked by two-dimensional echocardiography.
Assessment of renal function
Renal insufficiency was defined as an estimated GFR of
< 60 ml/min/1.73 m
2 calculated using the Modification
of Diet in Renal Disease (MDRD) [15] formula, includ-
ing age, ethnicity, sex, and serum creatinine: GFR, in
ml/min per 1.72 m
2 = 1.86 × (serum creatinine [ml/
min])
-1.154 × (age)
-0.203 × (0.742 [for women]). Serum
creatinine was analyzed by the alkaline picrate method
performed using an Olympus 5431
® device (Olympus
Optical Co. Ltd., Tokyo, Japan). The level of creatinine
was measured prior to angiography, and renal function
was assessed based on the estimation of GFR.
Study endpoint
The primary endpoints were major adverse cardiac
events (MACE), including a composite of all cause-of-
death, myocardial infarction, target lesion revasculariza-
tion, and coronary artery bypass graft during the 12-
month clinical follow-up. Target lesion revascularization
was defined as any revascularization of the target lesion
because of restenosis or reocclusion within the stent or
adjacent 5-mm border.
Statistical analysis
Continuous variables are presented as means ± SD, and
categorical variables as number of cases and
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t h eg r o u p so ra saw h o l eu s i n ge i t h e ra n a l y s i so fv a r -
iance (ANOVA) or Student’s t-test for continuous vari-
ables, and Pearson chi-square test or Fisher’s exact test
for categorical variables. Continuous variables with
skewed distribution were presented as median (with
25th and 75th percentiles) and compared by using the
Kruskal-Wallis test. Logistic regression was performed
to identify the independent predictors of MACE at 1-
year clinical follow-up. Multivariate Cox regression ana-
lysis was adjusted by previous medical knowledge and
independently of p value: age, sex, body mass index, sys-
tolic blood pressure on admission, heart rate, Killip class
> I, history of hypertension, dyslipidemia, coronary
artery disease, smoking, multivessel disease, LVEF <
55%, medication of statin, low-density lipoprotein cho-
lesterol, and N-terminal pro-brain natriuretic peptide
(NT-pro BNP) of > 3000 pg/ml. The probability of
death was estimated by the Kaplan-Meier method, and
curves were compared with the log-rank test. All statis-
tical tests were 2-tailed, and p < 0.05 was considered
significant. Analyses were performed using the Statistical
Package for Social Sciences software, version 17.0 (SPSS,
Chicago, Illinois).
Results
Baseline characteristics of the study patients
A total of 9905 patients with AMI were included in the
present study. The baseline characteristics of the
patients are listed in Table 1. Patients from Group I
toward Group IV were increasingly older, more fre-
quently women, had higher rates of previous hyperten-
sion episodes and coronary artery disease, were above
Killip class I, and exhibited increasing NT-pro BNP and
high-sensitivity C-reactive protein (hs-CRP). On the
contrary, the rate of smoking history, family history of
coronary artery disease, low-density lipoprotein choles-
terol levels, and LVEF decreased from Group I toward
Group IV. There were significant differences in heart
rate, systolic and diastolic blood pressure, previous dysli-
pidemia, and presence of STEMI or NSTEMI among the
groups. However, there were no differences in body
weight or body mass index. Group IV had significantly
higher rate of insulin treatment compared to Group II,
but there were no differences in oral hypoglycemic
agents between the 2 groups. In-hospital medications
are also listed in Table 1. It is noteworthy that Group
IV had higher levels of creatinine and lower estimated
GFR.
Angiographic and procedural characteristics
The coronary angiographic and procedural characteris-
tics are listed in Table 2. The number of involved coron-
ary arteries was increasingly higher in patients of Group I
through IV. The number of complex lesions (B2 and C)
as defined by the American College of Cardiology/Ameri-
can Heart Association (ACC/AHA) was also increasingly
higher. Moreover, post-procedure thrombolysis in myo-
cardial infarction (TIMI) flow was lower in patients of
Group IV as compared with Group I.
In-hospital mortality and clinical outcomes during follow-
up
Clinical outcomes in hospital and at 1 month and 12
months after discharge are listed in Table 3. Group IV
had a significantly higher incidence of composite
MACE, myocardial infarction, and death after 1-month
and 12-month clinical follow-up. There was a stepwise
increase in 12-month composite MACE in patients of
Group I through IV (Figure 1). However, target lesion
revascularization at 1 month and coronary artery bypass
g r a f ta t1 2m o n t h sw e r en o ts i g n i f i c a n t l yd i f f e r e n t
among the groups. In patients with no renal insuffi-
ciency (Groups I and II), those with diabetes had signifi-
cantly more 12-month composite MACE than those
without diabetes (12.5% versus 15.7%, respectively; p =
0.001). In patients with renal insufficiency (Groups III
and IV), the same was observed (30.5% versus 36.5%,
respectively; p = 0.002). However, there were no signifi-
cant differences between diabetic and non-diabetic
patients with regard to 12-month mortality in the renal
insufficiency groups (25.3% in Group III versus 27.5% in
Group IV; p = 0.212). Thus, both myocardial infarction
and target lesion revascularization might be affecting the
increase of 12-month composite MACE in diabetic
patients with renal insufficiency. Kaplan-Meier curve
analysis (Figure 2) revealed that patients with diabetes
had significantly higher death rates than those without
diabetes under no renal insufficiency conditions (p =
0.006). The same was not observed in diabetic and non-
diabetic patients with renal insufficiency (p = 0.288).
Cox regression analysis for mortality during follow-up
Multivariable Cox regression analysis was performed to
identify the risk factor(s) accounting for the correlation
effect of renal insufficiency and diabetes in 12-month
mortality. The results of a multivariable Cox propor-
tional hazards model adjusting for other potential clini-
cal predictors of mortality are shown in Table 4. After
adjusting for multiple covariates, Group II (diabetes and
no renal insufficiency) showed no significant differences
in 12-month mortality as compared with Group I (no
diabetes and no renal insufficiency) (hazard ratio [HR],
1.20; 95% confidence interval [CI], 0.86-2.02; p =0 . 2 0 9 ) .
However, the 12-month mortality increased stepwise
from Group III to Group IV as compared with Group I
(HR, 1.96; 95% CI, 1.34-2.86; p = 0.001; and HR, 2.42;
95% CI, 1.62-3.62; p < 0.001, respectively).
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Group I (n = 5700) Group II (n = 1730) Group III (n = 1431) Group IV (n = 1044) p Value
Overall Linear†
Age (years) 61 ± 13 62 ± 11
¶ 71 ± 11 70 ± 9
‡§ < 0.001
Age groups (years) < 0.001 < 0.001
< 65 2671(47%) 706(41%) 231(16%) 136(13%)
65-74 2165(38%) 781(45%) 598(42%) 586(56%)
≥ 75 864(15%) 243(14%) 602(42%) 322(31%)
Male (%) 4411(77) 1222(71)
¶ 812(57) 534 (51)
‡§ < 0.001 < 0.001
Body weight (kg) 65 ± 12 66 ± 12
¶ 61 ± 12 62 ± 11 0.095
Body mass index (kg/m
2) 2 4±3 2 5±4
¶ 23 ± 3 24 ± 3
§ 0.483
HR(beats/minute) 76 ± 20 80 ± 20
¶ 79 ± 31 83 ± 26
‡§ < 0.001
Systolic blood pressure(mm Hg) 130 ± 27 130 ± 28 121 ± 35 127 ± 34
‡ < 0.001
Diastolic blood pressure(mm Hg) 80 ± 19 79 ± 16 74 ± 21 76 ± 35
‡ < 0.001
Current smoker (%) 3690(65) 990(58)
¶ 660(46) 380(37)
‡§ < 0.001 < 0.001
Treatment of Diabetes mellitus
No treatment (%) 5700(100) 260(15.2) 1431(100) 65(7)
‡
Insulin treatment (%) 101(5.8) 160(15)
‡
Oral hypoglycemic agents (%) 1369(79) 819(78)
Previous hypertension (%) 2168(38) 987(57)
¶ 863(60) 772(74)
‡§ < 0.001 < 0.001
Previous dyslipidemia (%) 497(9) 212(12)
¶ 118(8) 133(13)
§ < 0.001 0.001
Family history of CAD (%) 446(8) 118(7) 63(4) 43(4)
‡ < 0.001 < 0.001
Previous CAD (%) 684(12) 311(18)
¶ 293(21) 273(26)
‡§ < 0.001 < 0.001
Killip class > I (%) 1099(20) 423 (25)
¶ 603 (43) 508 (50)
‡§ < 0.001 < 0.001
LDL-C (mg/dl) 120 ± 40 114 ± 38
¶ 112 ± 43 110 ± 52
‡ < 0.001
NT-proBNP (pg/ml) 323
(81, 1151)
468
(123, 1577)
1750 (338, 6804) 3522 (877, 10894) < 0.001
hs-CRP 0.64 (0.17, 3.53) 0.92 (0.23, 4.15) 1.46 (0.30, 6.59) 2.19 (0.36, 9.70) < 0.001
LVEF (%) 53 ± 12 51 ± 12
¶ 49 ± 14 46 ± 14
‡§ < 0.001
STEMI (%) 3619(64) 1009(58)
¶ 908(63) 518(50)
‡§ < 0.001
Non-STEMI (%) 2083(37) 722(42)
¶ 524(37) 526(50)
‡§ < 0.001
Kidney function
Serum Creatinine (mg/dL) 0.92 ± 0.19 0.91 ± 0.19
¶ 2.08 ± 3.58 2.38 ± 3.44
‡§ < 0.001
Estimated GFR* (ml/min/1.73 m
2) 88.9 ± 39.2 87.5 ± 32.9 44.7 ± 14.2 39.0 ± 15.9
‡§ < 0.001
Medications (%)
Aspirin 5616 (99) 1706 (99) 1381 (97) 1009(97)
‡ < 0.001 < 0.001
Clopidogrel 5523(97) 1675(97) 1340(94) 968(93)
‡ < 0.001 < 0.001
Beta blocker 4295 (76) 1337 (78) 908 (64) 694 (67)
‡ < 0.001 < 0.001
CCB 707(12) 215(13) 205(14) 208(20)
‡§ < 0.001 < 0.001
Statin 4274 (75) 1295 (75) 906 (64) 667 (64)
‡ < 0.001 < 0.001
ACE inhibitor 4191 (74) 1294 (75) 891 (63) 629 (60)
‡ < 0.001 < 0.001
ARB 656 (12) 249 (14)
¶ 235 (17) 213 (21)
‡§ < 0.001 < 0.001
Data are presented as mean ± SD or number of patients (percentage). Not normally distributed variables were described as median (25
th,7 5
th percentile). Group
I, estimated GFR ≥ 60(ml/min/1.73 m
2) without DM; Group II, estimated GFR ≥ 60 with DM; Group III, estimated GFR < 60 without DM; Group IV, estimated GFR <
60 with DM.
Abbreviations: HR, heart rate; CAD, coronary arterial disease; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-
CRP, high-sensitivity C-Reactive Protein; LVEF, left ventricular ejection fraction; STEMI, ST-segment elevation acute myocardial infarction; GFR, Glomerular filtration
rate; CCB, calcium channel blocker; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blockers.
*On the basis of abbreviated MDRD (Modification of Diet in Renal Disease) study equation.
†Statistical significance for linear-by-linear association between categorical variables calculated using chi-square-test for trend.
¶ p < 0.05 Compared with Group I.
‡p < 0.05 Compared with Group II.
§ p < 0.05 Compared with Group III.
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Group I (n = 5700) Group II (n = 1730) Group III (n = 1431) Group IV (n = 1044) p Value
Overall Linear†
Location of culprit coronary lesion (%)
Left anterior descending 2599(50) 759(47)
¶ 500(42) 365(42)
‡ < 0.001 < 0.001
Left circumflex 888(17) 271(17) 179(15) 143(17) 0.354 0.208
Right 1639(32) 544(34) 480(40) 326(38)
‡ < 0.001 < 0.001
Left main 77(2) 40(3)
¶ 40(3) 35(4)
‡ < 0.001 < 0.001
No. of coronary arteries narrowed (%)
One vessel 2552(49) 580(36)
¶ 407(34) 203(23)
‡§ < 0.001 < 0.001
Two vessel 1524(29) 512(32) 388(32) 244(28)
‡§ 0.039 0.543
Three vessel 998(19) 455(28)
¶ 354(30) 372(43)
‡§ < 0.001 < 0.001
Multi-vessel 2645(51) 1041(64)
¶ 789(66) 673(77)
‡§ < 0.001 < 0.001
ACC/AHA lesion score (%)
A 235 (5) 63(4) 49(4) 35(4) 0.679 0.342
B1 855(18) 283(19) 174(16) 126(15)
‡ 0.087 0.078
B2 1384(28) 449(30) 262(23) 204(25)
‡ 0.001 0.002
C 2415(49) 724(48) 635(57) 455(56)
‡ < 0.001 < 0.001
Post-procedure TIMI flow ≥ III (%) 4541(93) 1394(93) 970(88) 689(88)
‡ < 0.001 < 0.001
Groups are as in Table 1.
Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; TIMI, thrombolysis in myocardial infarction.
†Statistical significance for linear-by-linear association between categorical variables calculated using chi-square-test for trend.
¶ p < 0.05 Compared with Group I.
‡p < 0.05 Compared with Group II.
§ p < 0.05 Compared with Group III.
Table 3 Clinical outcomes in-hospital period and follow up.
Group I (n = 5702) Group II (n = 1731) Group III (n = 1432) Group IV (n = 1044) p Value
Overall Linear†
In-hospital outcomes (n = 9905)
In-hospital death (%) 168(3) 66(4) 249(18) 185(18)
‡ < 0.001 < 0.001
1-month outcomes
Composite MACE (%) 327 (5.7) 128(7.4)
¶ 317(22.2) 257(24.6)
‡ < 0.001 < 0.001
Death (%) 225(3.9) 84(4.9) 296(20.7) 226(21.6)
‡ < 0.001 < 0.001
MI (%) 28(0.5) 12(0.7) 4(0.3) 19(1.8)
‡ < 0.001 0.001
Re-PCI (%) 57(1.0) 21(1.2) 16(1.1) 7(0.7) 0.559 0.649
CABG (%) 17(0.3) 11(0.6) 1(0.1) 5(0.5) 0.039 0.807
12-month outcomes
Composite MACE (%) 715 (12.5) 271 (15.7)
¶ 436 (30.5) 381 (36.5)
‡§ < 0.001 < 0.001
Death (%) 287(5.0) 117 (6.8)
¶ 361 (25.3) 287 (27.5)
‡ < 0.001 < 0.001
MI (%) 44(0.8) 20 (1.2) 10 (0.7) 25 (2.4)
‡§ < 0.001 < 0.001
Re-PCI (%) 385(6.3) 120 (6.9) 59 (4.1) 62 (5.9)
§ 0.006 0.082
CABG (%) 26 (0.5) 14 (0.8) 6 (0.4) 7 (0.7) 0.280 0.455
Groups are as in Table 1.
Abbreviations: MACE, major adverse cardiac event; MI, myocardial infarction; Re-PCI, target lesion revascularization; CABG, coronary artery bypass graft.
†Statistical significance for linear-by-linear association between categorical variables calculated using chi-square-test for trend.
¶ p < 0.05 Compared with Group I.
‡p < 0.05 Compared with Group II.
§ p < 0.05 Compared with Group III.
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We performed multivariate logistic regression analysis to
identify the independent predictors of MACE. Predictors
of 12-month MACE were Killip class > I, diabetes melli-
tus, previous coronary artery disease, decrease in LVEF
by < 55%, estimated GFR of < 60 ml/min/1.73 m
2,a n d
increase in levels of NT-pro BNP by > 3000 pg/ml. On
the other hand, in-hospital prescription of beta-blockers
and statins were negative predictors of 12-month MACE
(Table 5).
Discussion
This study was designed to investigate the clinical out-
comes of patients with AMI as function of the presence
or absence of renal dysfunction and diabetes. Many clin-
ical studies have been conducted on the association
between renal dysfunction and mortality among patients
with AMI [1,2,6,16] or have evaluated the influence of
diabetes on mortality following acute coronary syn-
drome [11,17-20]. In fact, renal dysfunction and diabetes
are associated with adverse clinical outcomes after AMI.
However, limited information exists with regard to car-
diovascular disease risk in patients with diabetes and
renal dysfunction, particularly after AMI. It is also
unknown whether the relation between diabetes and
cardiovascular outcomes differs between patients with
or without renal dysfunction.
Correlation between clinical outcomes and presence of
renal insufficiency and diabetes in patients with AMI
Our findings confirm those of previous studies [1,2,6,16]
that deteriorating renal function predicts mortality after
AMI. In our study, renal insufficiency groups (Group III
and IV) had higher composite MACE occurrence and
mortality after a 12-month follow-up as compared with
groups with no renal insufficiency. There are several
potential links between renal insufficiency and increased
number of cardiovascular events. First of all, renal insuf-
ficiency is accompanied by anemia, high level of homo-
cysteine, increased oxidation of low-density lipoproteins,
and diminished nitric oxide production, which may
result in accelerated atherosclerosis, endothelial dysfunc-
tion, and poor outcome after myocardial infarction
[21-23]. In addition, left ventricular hypertrophy accom-
panying advanced renal failure is an important risk fac-
tor for mortality resulting from cardiovascular disease.
Figure 1 Composite MACE at 12-month stratified by the
presence diabetes mellitus (DM) and renal insufficiency (RI).
Figure 2 Kaplan-Meier curves according to renal insufficiency in patients with or without diabetes mellitus (DM).
Table 4 Prognostic values of combined use of renal
insufficiency and diabetes mellitus for 12 months
mortality (Cox proportional hazards model)
Hazard Ratio (95% confidence interval)
No adjustment P value Adjustment P value
Group I**
Group II 1.35 (1.09-1.68) 0.006 1.32 (0.86-2.02) 0.209
Group III 5.65 (4.84-6.60) < 0.001 1.96 (1.34-2.86) 0.001
Group IV 6.14 (5.21-7.23) < 0.001 2.42 (1.62-3.62) < 0.001
**Reference group
Group I, estimated GFR ≥ 60(ml/min/1.73 m
2) without DM; Group II, estimated
GFR ≥ 60 with DM; Group III, estimated GFR < 60 without DM; Group IV,
estimated GFR < 60 with DM. Adjusted for factors included in age, sex, body
mass index, systolic blood pressure on admission, heart rate, Killip class > I,
history of hypertension, dyslipidemia, coronary artery disease, smoking, multi
vessel disease, LVEF < 55%, medication of statins, low-density lipoprotein
cholesterol, NT-pro BNP of > 3000 (pg/ml).
Kim et al. Cardiovascular Diabetology 2011, 10:95
http://www.cardiab.com/content/10/1/95
Page 6 of 10In the clinical setting, renal insufficiency might be
another useful surrogate marker for cardiovascular dis-
ease in the patients with diabetes, because the estimated
GFR was associated with both the intima-media thick-
ness and the brachial-ankle pulse wave velocities in pre-
vious study [24]. Moreover, diabetic patients with non-
albuminuric renal impairment had higher prevalence of
cardiovascular disease than those with albuminuria and
non-reduced estimated GFR [25-27]. Therefore, renal
impairment is a powerful predictor of cardiovascular
disease morbidity and mortality in diabetic patients.
Similarly, in our study, angiographic findings such as
left main coronary artery disease and ACC/AHA lesion
scores were more severe in renal insufficiency than in
non-renal insufficiency groups.
Diabetic patients with AMI hold poorer clinical out-
comes than non-diabetic patients [19]. Our findings
supported the observation that patients with diabetes
have more composite MACE at 1 year of follow-up than
those without diabetes, regardless of renal insufficiency.
Multiple mechanisms have been implicated in the
increased number of adverse outcomes in diabetes
patients. These mechanisms include an abnormal meta-
bolic response to ischemia with inefficient energy use
and accumulation of deleterious oxygen-free radicals
[28], greater endothelial dysfunction [29], and abnormal-
ities of thrombosis and fibrinolysis [30]. Recently, Yan et
al. [31] demonstrated a significant association between
plasma osteopontin levels and the presence and severity
of coronary artery disease in diabetic patients, indicating
that osteopontin may be critically involved in the
inflammatory processes resulting in accelerated athero-
sclerosis. Patients with diabetes are known to have a
greater atherosclerosis burden, with more diffuse and
more multivessel coronary artery disease, as seen in our
study.
Taking all our findings together, we suggest that con-
comitant occurrence of renal insufficiency and diabetes
in patients with AMI represent not only severity of dis-
ease or clinical outcome, but also serve as prognostic
predictor of cardiovascular risk, including composite
MACE and all-cause mortality.
Clinical relevance of the classification according to renal
insufficiency and diabetes in patients with AMI
The present study demonstrated that simply categoriz-
ing patients into 4 groups according to the presence and
absence of diabetes and renal insufficiency was efficient
in differentially predicting 1-year clinical outcome after
AMI. Despite no significant differences between Group I
and Group II in multivariate Cox regression analysis, we
found a stepwise increase in the HR for 12-month mor-
tality from Group I through Group IV. These observa-
tions were further supported by the fact that patients in
higher groups were older, had a higher prevalence of
hypertension and previous coronary artery disease, and
lower LVEF compared with Group I, all of which may
induce atherosclerosis and contribute to increased cardi-
ovascular mortality. In this respect, we also found that
several molecular markers, including NT-pro BNP and
hs-CRP were increased from Group I through IV. Such
markers are affected not only by the degree of heart fail-
ure, but also by inflammation [32,33], which might have
increased the risk of cardiovascular mortality in our
patients with AMI. Therefore, this study suggests that
categorization of patients according to the presence of
Table 5 Independent predictors of One-year Major Adverse Cardiac Events
Odd ratio (95% confidence interval) P value
Killip > I 1.48(1.24-1.76) < 0.001
Hypertension 1.04(0.89-1.23) 0.616
Diabetes mellitus 1.26(1.03-1.45) 0.019
Dyslipidemia 0.84(0.64-1.10) 0.197
Previous CAD 1.49(1.22-1.82) < 0.001
History of smoking 1.01(0.86-1.18) 0.931
Familial history of CAD 1.01(0.74-1.38) 0.949
LVEF < 55% 1.23(1.04-1.46) 0.017
Estimated GFR* < 60 (ml/min/1.73 m
2) 1.45(1.21-1.75) < 0.001
NT-proBNP > 3000 (pg/ml) 2.17(1.79-2.64) < 0.001
Aspirin 0.63(0.28-1.45) 0.281
Beta blocker 0.72(0.59-0.88) 0.001
ACE inhibitor 0.92(0.75-1.12) 0.393
ARB 0.85(0.67-1.08) 0.184
Statin 0.80(0.67-0.95) 0.012
*On the basis of abbreviated MDRD (Modification of Diet in Renal Disease) study equation.
Abbreviations: CAD, coronary arterial disease; LVEF, left ventricular ejection fraction; GFR, Glomerular filtration rate; NT-proBNP, N-terminal pro brain natriuretic
peptide; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blockers.
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mation for early-risk stratification of patients with AMI.
Recently, a single-center prospective study [13]
encompassing 3334 AMI patients divided into those
without diabetes, with diabetes and chronic kidney dis-
ease (CKD), and with diabetes and without CKD, sug-
gested that mortality and MACE rates did not differ
significantly between diabetes patients without CKD and
patients without diabetes. Diabetes coexisting with CKD,
however, was found to be one of the strongest indepen-
dent risk factors for cardiovascular complications and
total mortality, in agreement with our findings. On the
other hand, some differences in the clinical outcomes
were observed in our study. The non-diabetic patients
were divided into 2 groups according to presence or
absence of renal insufficiency, and non-diabetic patients
with renal insufficiency (Group III) had higher mortality
and 12-month composite MACE than diabetic patients
without renal insufficiency (Group II). On the contrary,
patients without diabetes and renal insufficiency (Group
I) had less severe adverse clinical outcomes following
AMI than diabetic patients without renal insufficiency
(Group II).
Anavekar et al. [12] showed that patients with or with-
out diabetes present a similar relationship between renal
insufficiency and cardiovascular risk, including all-cause
mortality, death, a composite of heart failure, recurrent
AMI, resuscitated sudden cardiac death, and stroke, after
high-risk AMI. In agreement with a previous study [12],
our study demonstrated that the mortality at 12 months
of follow-up was not different between diabetic and non-
diabetic patients with renal insufficiency after AMI. This
indicates that patients with renal dysfunction might be
m o r es u s c e p t i b l et os e v e r ea n dd i f f u s ec o r o n a r ya r t e r y
disease, regardless of diabetes. Indeed, such patients pre-
sent a high prevalence of left ventricular hypertrophy and
hypertension, both of which are markers of increased car-
diovascular risk [34,35].
Although patients with and without diabetes experi-
ence increased cardiovascular event rates with worsen-
ing of renal function, patients with diabetes consistently
show higher proportions of events than non-diabetic
patients according to decreasing renal function [12].
Consequently, diabetes and renal insufficiency indepen-
dently or synergistically are related with an increase in
cardiovascular events after AMI. Therefore, we under-
line the importance of classifying patients into 4 large
groups according to presence or absence of diabetes and
renal insufficiency for predicting mortality and cardio-
vascular complications in patients following AMI.
Study limitations
Nonetheless, the present study has several limitations.
The best validated method to calculate estimated GFR is
the MDRD formula. However, this formula has not been
specifically validated in patients with diabetes [36]. With
respect to increasing GFR in patients with early diabetes,
the influence of GFR changes was not addressed. In
addition, even healthy but more than 65 years old
female subjects can reach a GFR of less than 60 ml/
min/1.73 m
2, indicating that the definition of renal
insufficiency is weak. Secondly, since our study was ret-
rospective and non-randomized, it may reflect selection
b i a s .T h i r d ,a l t h o u g hm o s tc o n f o u n d e r sw e r ei n c l u d e d
in the multivariate analysis, it is possible that some con-
founders were excluded. Finally, clinical data encom-
passed a 1-year period in our study. Thus, long-term
clinical outcomes could not be fully evaluated. Large-
scale long-term prospective randomized trials are
needed in the future.
Conclusions
Renal insufficiency, especially in association with dia-
betes, is associated with the occurrence of composite
MACE and is a predictor of poor prognosis in patients
with AMI. Categorization of patients according to pre-
sence or absence of diabetes and renal insufficiency pro-
vides valuable information for early-risk stratification of
patients with AMI.
Abbreviations
ACC/AHA: American College of Cardiology/American Heart Association; AMI:
acute myocardial infarction; CI: confidence interval; CKD: chronic kidney
disease; ESRD: end-stage renal disease; GFR: glomerular filtration rate; GRACE:
Global Registry of Acute Coronary Events; HR: hazard ratio; hs-CRP: high-
sensitivity C-reactive protein; KAMIR: Korea Acute Myocardial Infarction
Registry; LVEF: left ventricular ejection fraction; MACE: major adverse cardiac
events; MDRD: Modification of Diet in Renal Disease; NSTEMI: non-ST-
segment elevation acute myocardial infarction; NT-pro BNP: N-terminal pro-
brain natriuretic peptide; PCI: percutaneous coronary intervention; STEMI: ST-
segment elevation acute myocardial infarction; TIMI: thrombolysis in
myocardial infarction.
Acknowledgements
This work was supported by a grant of the Korea Healthcare technology
R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea
(A084869). The authors thank the KAMIR investigators for participating in this
study.
Korea Acute Myocardial infarction Registry (KAMIR) Investigators
Myung Ho Jeong, Young Keun Ahn, Sung Chull Chae, Jong Hyun Kim,
Seung Ho Hur, Young Jo Kim, In Whan Seong, Dong Hoon Choi, Jei Keon
Chae, Taek Jong Hong, Jae Young Rhew, Doo Il Kim, In Ho Chae, Jung Han
Yoon, Bon Kwon Koo, Byung Ok Kim, Myoung Yong Lee, Kee Sik Kim, Jin
Yong Hwang, Myeong Chan Cho, Seok Kyu Oh, Nae Hee Lee, Kyoung Tae
Jeong, Seung Jea Tahk, Jang Ho Bae, Seung Woon Rha, Keum Soo Park,
Chong Jin Kim, Kyoo Rok Han, Tae Hoon Ahn, Moo Hyun Kim, Ki Bae Seung,
Wook Sung Chung, Ju Young Yang, Chong Yun Rhim, Hyeon Cheol Gwon,
Seong Wook Park, Young Youp Koh, Seung Jae Joo, Soo Joong Kim, Dong
Kyu Jin, Jin Man Cho, Byung Ok Kim, Sang-Wook Kim, Jeong Kyung Kim, Tae
Ik Kim, Deug Young Nah, Si Hoon Park, Sang Hyun Lee, Seung Uk Lee,
Hang-Jae Chung, Jang Hyun Cho, Seung Won Jin, Yang Soo Jang, Jeong
Gwan Cho, and Seung Jung Park.
Author details
1Department of Internal Medicine, Chonnam National University Medical
School, Gwangju, Korea.
2Cardiovascular Research Institute of Chonnam
Kim et al. Cardiovascular Diabetology 2011, 10:95
http://www.cardiab.com/content/10/1/95
Page 8 of 10National University, Gwangju, Korea.
3Department of Internal Medicine,
Yeungnam University, Daegu, Korea.
4Department of Internal Medicine,
Chungbuk National University, Cheongju, Korea.
5Department of Internal
Medicine, Kyunghee University, Seoul, Korea.
Authors’ contributions
CSK carried out the research design, performed the statistical analysis and
final preparation of the manuscript. JSC contributed in its design,
performance. JWP and EHB participated in the design of this study. SKM
contributed in the research design and result interpretation. MHJ, YJK, MCC
and CJK participated in Korea Acute Myocardial Infarction Registry (KAMIR).
SWK contributed in the research design, results interpretation and final
preparation of the manuscript. The KAMIR investigators furnished valuable
data. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 October 2011 Accepted: 31 October 2011
Published: 31 October 2011
References
1. Amin AP, Spertus JA, Reid KJ, Lan X, Buchanan DM, Decker C, Masoudi FA:
The prognostic importance of worsening renal function during an acute
myocardial infarction on long-term mortality. Am Heart J 2010,
160:1065-1071.
2. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL,
White HD, Nordlander R, Maggioni A, Dickstein K, et al: Relation between
renal dysfunction and cardiovascular outcomes after myocardial
infarction. N Engl J Med 2004, 351:1285-1295.
3. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute
myocardial infarction among patients on long-term dialysis. N Engl J Med
1998, 339:799-805.
4. Keough-Ryan TM, Kiberd BA, Dipchand CS, Cox JL, Rose CL, Thompson KJ,
Clase CM: Outcomes of acute coronary syndrome in a large Canadian
cohort: impact of chronic renal insufficiency, cardiac interventions, and
anemia. Am J Kidney Dis 2005, 46:845-855.
5. Walsh CR, O’Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM:
Elevated serum creatinine is associated with 1-year mortality after acute
myocardial infarction. Am Heart J 2002, 144:1003-1011.
6. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM,
Granger CB, Ohman EM, Holmes DR Jr: Prognostic implications of
abnormalities in renal function in patients with acute coronary
syndromes. Circulation 2002, 106:974-980.
7. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL,
Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction
and renal dysfunction: a high-risk combination. Ann Intern Med 2002,
137:563-570.
8. Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation
2002, 106:3143-3421.
9. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M: Global and
regional mortality from ischaemic heart disease and stroke attributable
to higher-than-optimum blood glucose concentration: comparative risk
assessment. Lancet 2006, 368:1651-1659.
10. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M,
Steg PG, Gowda N, Gore JM: Implications of diabetes in patients with
acute coronary syndromes. The Global Registry of Acute Coronary
Events. Arch Intern Med 2004, 164:1457-1463.
11. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA,
Cannon CP, Antman EM: Diabetes and mortality following acute coronary
syndromes. JAMA 2007, 298:765-775.
12. Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R,
White H, Kober L, Velazquez E, Pfeffer MA: Comparison of renal function
and cardiovascular risk following acute myocardial infarction in patients
with and without diabetes mellitus. Am J Cardiol 2008, 101:925-929.
13. Kowalczyk J, Lenarczyk R, Strojek K, Zielinska T, Gumprecht J, Sedkowska A,
Kukulski T, Swierad M, Kowalski O, Sredniawa B, et al: Prognosis in diabetic
patients with acute myocardial infarction treated invasively is related to
renal function. Med Sci Monit 2010, 16:CR67-74.
14. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction
redefined–a consensus document of The Joint European Society of
Cardiology/American College of Cardiology Committee for the
redefinition of myocardial infarction. J Am Coll Cardiol 2000, 36:959-969.
15. Mariat C, Alamartine E, Berthoux F: Measured and estimated glomerular
filtration rate. N Engl J Med 2006, 355:1068-1069, author reply 1069-1070.
16. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M,
McCullough PA: Determinants of mortality after myocardial infarction in
patients with advanced renal dysfunction. Am J Kidney Dis 2001,
37:1191-1200.
17. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F,
Avezum A, Goodman SG, Flather MD, Anderson FA Jr, Granger CB:
Prediction of risk of death and myocardial infarction in the six
months after presentation with acute coronary syndrome:
prospective multinational observational study (GRACE). BMJ 2006,
333:1091.
18. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from
coronary heart disease in subjects with type 2 diabetes and in
nondiabetic subjects with and without prior myocardial infarction. N
Engl J Med 1998, 339:229-234.
19. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG,
Califf RM, Topol EJ: Influence of diabetes mellitus on clinical outcome in
the thrombolytic era of acute myocardial infarction. GUSTO-I
Investigators. Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997,
30:171-179.
20. Rasoul S, Ottervanger JP, Timmer JR, Yokota S, de Boer MJ, van ‘t Hof AW:
Impact of diabetes on outcome in patients with non-ST-elevation
myocardial infarction. Eur J Intern Med 2011, 22:89-92.
21. Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing the cardiac
risk profile in chronic hemodialysis patients: a hypothesis on the role of
oxidant stress and other non-traditional cardiac risk factors. J Am Soc
Nephrol 1997, 8:475-486.
22. Bostom AG, Culleton BF: Hyperhomocysteinemia in chronic renal disease.
J Am Soc Nephrol 1999, 10:891-900.
23. Luft FC: Renal disease as a risk factor for cardiovascular disease. Basic Res
Cardiol 2000, 95(Suppl 1):I72-76.
24. Ito H, Komatsu Y, Mifune M, Antoku S, Ishida H, Takeuchi Y, Togane M: The
estimated GFR, but not the stage of diabetic nephropathy graded by
the urinary albumin excretion, is associated with the carotid intima-
media thickness in patients with type 2 diabetes mellitus: a cross-
sectional study. Cardiovasc Diabetol 2010, 9:18.
25. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R,
Vedovato M, Gruden G, Cavalot F, et al: Clinical significance of
nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011,
29:1802-1809.
26. Ritz E, Schmieder RE, Pollock CA: Renal protection in diabetes: lessons
from ONTARGET. Cardiovasc Diabetol 2010, 9:60.
27. Pugliese G, Solini A, Fondelli C, Trevisan R, Vedovato M, Nicolucci A,
Penno G: Reproducibility of albuminuria in type 2 diabetic subjects.
Findings from the Renal Insufficiency And Cardiovascular Events (RIACE)
Study. Nephrol Dial Transplant 2011.
28. Young ME, McNulty P, Taegtmeyer H: Adaptation and maladaptation of
the heart in diabetes: Part II: potential mechanisms. Circulation 2002,
105:1861-1870.
29. Mulvihill NT, Foley JB, Murphy RT, Pate G, Crean PA, Walsh M: Enhanced
endothelial activation in diabetic patients with unstable angina and
non-Q-wave myocardial infarction. Diabet Med 2001, 18:979-983.
30. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management. JAMA 2002,
287:2570-2581.
31. Yan X, Sano M, Lu L, Wang W, Zhang Q, Zhang R, Wang L, Chen Q,
Fukuda K, Shen W: Plasma concentrations of osteopontin, but not
thrombin-cleaved osteopontin, are associated with the presence and
severity of nephropathy and coronary artery disease in patients with
type 2 diabetes mellitus. Cardiovasc Diabetol 2010, 9:70.
32. Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O:
Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin
Res Cardiol 2010, 99:445-452.
33. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ,
Stehouwer CD: Impaired renal function is associated with markers of
Kim et al. Cardiovascular Diabetology 2011, 10:95
http://www.cardiab.com/content/10/1/95
Page 9 of 10endothelial dysfunction and increased inflammatory activity. Nephrol Dial
Transplant 2003, 18:892-898.
34. Benetos A, Waeber B, Izzo J, Mitchell G, Resnick L, Asmar R, Safar M:
Influence of age, risk factors, and cardiovascular and renal disease on
arterial stiffness: clinical applications. Am J Hypertens 2002, 15:1101-1108.
35. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP,
Levey AS: Atherosclerotic cardiovascular disease risks in chronic
hemodialysis patients. Kidney Int 2000, 58:353-362.
36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate
method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999, 130:461-470.
doi:10.1186/1475-2840-10-95
Cite this article as: Kim et al.: Concomitant renal insufficiency and
diabetes mellitus as prognostic factors for acute myocardial infarction.
Cardiovascular Diabetology 2011 10:95.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kim et al. Cardiovascular Diabetology 2011, 10:95
http://www.cardiab.com/content/10/1/95
Page 10 of 10